keynote-028 and keynote-158: pembrolizumab as treatment for advanced sclc after two or more line...
Published 5 years ago • 171 plays • Length 3:32Download video MP4
Download video MP3
Similar videos
-
4:54
background of the keynote-158 trial for pembrolizumab in advanced mesothelioma
-
6:32
keynote trials show pembrolizumab benefited patients with advanced small cell lung cancer
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
7:13
first-line pembrolizumab plus chemotherapy for patients with advanced squamous nsclc: 3-year fol...
-
3:14
keynote-062 study: pembrolizumab as treatment for advanced gastroesophageal junction and gastric...
-
3:37
pembrolizumab plus chemo as firstline therapy for nsclc
-
3:34
asco 2018 - keynote 158 - keytruda in previously treated, now relapsing patients with sclc
-
4:57
keynote-024 shows prolonged nsclc survival benefit with pembrolizumab | julie brahmer
-
6:32
latest results from keynote-181: pembrolizumab versus chemotherapy as a second-line therapy for ...
-
5:00
implications for pembrolizumab in nsclc
-
7:50
keynote-598: pembrolizumab with ipilimumab or placebo in patients with untreated metastatic nsclc
-
3:10
pembrolizumab new option for firstline treatment of advanced lung cancer with high pdl-1 expression
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
4:20
keynote-604: pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-sta...
-
3:47
pembrolizumab as treatment for oligometastatic nsclc
-
3:31
the keynote-024 precedent for advanced-nsclc treatment
-
1:39
pembrolizumab and epacadostat for nsclc: echo-306/keynote-715
-
1:53
dr. spigel on pembrolizumab/chemo combo in first-line nsclc
-
2:44
pembrolizumab and chemotherapy in advanced nsclc